Influence of the interval between transcatheter arterial embolization and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma
10.3969/j.issn.1001-5256.2022.10.016
- VernacularTitle:肝动脉栓塞联合射频消融间隔时间对小肝癌临床疗效的影响
- Author:
Yu SUN
1
;
Honghai ZHANG
1
;
Jiang LONG
1
;
Shoupeng SHENG
1
;
Jiasheng ZHENG
1
;
Yonghong ZHANG
1
Author Information
1. Center of Interventional Oncology and Liver Diseases, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
- Publication Type:Original Article_Liver Neoplasms
- Keywords:
Carcinoma, Hepatocellular;
Embolization, Therapeutic;
Local Ablation;
Treatment Outcome
- From:
Journal of Clinical Hepatology
2022;38(10):2286-2289
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the influence of the interval between transcatheter arterial embolization (TAE) and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma. Methods A total of 70 patients with hepatocellular carcinoma who received treatment in Beijing YouAn Hospital, Capital Medical University, from January 2019 to June 2020 were enrolled and divided into observation group (radiofrequency ablation was performed on the day or the second day of TAE) and control group (radiofrequency ablation was performed at 1-2 weeks after TAE) using a random number table, with 35 patients in each group. The independent samples t -test was used for comparison of continuous data between two groups, and the paired t -test was used for comparison of observation indicators before and after surgery; the chi-square test was used for comparison of categorical data between two groups. Results The observation group had a significantly shorter length of hospital stay than the control group (7.80±2.76 days vs 14.31±2.19 days, t =-10.93, P < 0.001). There were no significant differences between the observation group and the control group in complete ablation rate (95.12% vs 95.00%, χ 2 =0.001, P =0.980), incidence rate of adverse reactions (25.71% vs 20.00%, χ 2 =0.324, P =0.569), and 1-year recurrence rate (11.43% vs 14.29%, χ 2 =0.128, P =0.721), and there were also no significant differences in laboratory markers between the two groups before and after treatment (all P > 0.05). Conclusion TAE combined with sequential radiofrequency ablation at a short interval is safe and effective in the treatment of small hepatocellular carcinoma and can significantly shorten the length of hospital stay and reduce hospital costs, and therefore, it holds promise for clinical application.
